LAUSR

Value of Onconeural Antibodies in Checkpoint Inhibitor-Related Toxicities Alberto Vogrig, MD , Sergio Muñiz-Castrillo, MD , and Jérôme Honnorat, MD, PhD An increasing number of patients will be exposed to immune checkpoint inhibitors (ICIs) in the forthcoming future; therefore, it is crucial for neurologists to acquire experience in managing neurological immune-related adverse events (n-irAEs) associated with their use. Dubey et al recently described in Annals of Neurology 28 patients with n-irAEs. Surprisingly, they stated that in both the literature and in their series the neurological presentations rarely mimicked those of classical paraneoplastic neurological syndromes (PNSs). Moreover, they suspected that “these